96 
  
    
  
   Normal 
   0 
   
   
   
   
   false 
   false 
   false 
   
   EN-US 
   ZH-CN 
   X-NONE 
   
    
    
    
    
    
    
    
    
    
    
   
   
    
    
    
    
    
    
    
    
    
    
    
    
    
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
   
 
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:DengXian;
	mso-ascii-font-family:DengXian;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:DengXian;
	mso-hansi-theme-font:minor-latin;
	mso-font-kerning:1.0pt;
	mso-fareast-language:ZH-CN;}
 
      
  
   
   96 
  
    
  
   Normal 
   0 
   
   
   
   
   false 
   false 
   false 
   
   EN-US 
   ZH-CN 
   X-NONE 
   
    
    
    
    
    
    
    
    
    
    
   
   
    
    
    
    
    
    
    
    
    
    
    
    
    
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
   
 
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:DengXian;
	mso-ascii-font-family:DengXian;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:DengXian;
	mso-hansi-theme-font:minor-latin;
	mso-font-kerning:1.0pt;
	mso-fareast-language:ZH-CN;}
 
      
  
   
   96 
  
    
  
   Normal 
   0 
   
   
   
   
   false 
   false 
   false 
   
   EN-US 
   ZH-CN 
   X-NONE 
   
    
    
    
    
    
    
    
    
    
    
   
   
    
    
    
    
    
    
    
    
    
    
    
    
    
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
   
 
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:DengXian;
	mso-ascii-font-family:DengXian;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:DengXian;
	mso-hansi-theme-font:minor-latin;
	mso-font-kerning:1.0pt;
	mso-fareast-language:ZH-CN;}
 
      
  
   
   96 
  
    
  
   Normal 
   0 
   
   
   
   
   false 
   false 
   false 
   
   EN-US 
   ZH-CN 
   X-NONE 
   
    
    
    
    
    
    
    
    
    
    
   
   
    
    
    
    
    
    
    
    
    
    
    
    
    
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
   
 
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:DengXian;
	mso-ascii-font-family:DengXian;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:DengXian;
	mso-hansi-theme-font:minor-latin;
	mso-font-kerning:1.0pt;
	mso-fareast-language:ZH-CN;}
 
      
  
   
   96 
  
    
  
   Normal 
   0 
   
   
   
   
   false 
   false 
   false 
   
   EN-US 
   ZH-CN 
   X-NONE 
   
    
    
    
    
    
    
    
    
    
    
   
   
    
    
    
    
    
    
    
    
    
    
    
    
    
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
   
 
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:DengXian;
	mso-ascii-font-family:DengXian;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:DengXian;
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:DengXian;
	mso-hansi-theme-font:minor-latin;
	mso-font-kerning:1.0pt;
	mso-fareast-language:ZH-CN;}
 
  Ekso Bionics® (EKSO) is a worldwide pioneer in the field of robotic exoskeletons. For over 10 years they have been committed to developing the latest technology and engineering to help people rethink current physical limitations and achieve the remarkable. Their products unlock human strength, endurance, and mobility potential, with broad applications across medical and industrial markets. In 2016, Ekso Bionics received the first FDA clearance exoskeleton for use with stroke and spinal cord injury levels to C7. They have yet to imagine all human robotics applications and remain committed to forming strategic partnerships for cutting-edge innovation.

Ekso Bionics® (EKSO) is a worldwide pioneer in the field of robotic exoskeletons. For over 10 years they have been committed to developing the latest technology and engineering to help people rethink current physical limitations and achieve the remarkable. Their products unlock human strength, endurance, and mobility potential, with broad applications across medical and industrial markets. In 2016, Ekso Bionics received the first FDA clearance exoskeleton for use with stroke and spinal cord injury levels to C7. They have yet to imagine all human robotics applications and remain committed to forming strategic partnerships for cutting-edge innovation.